Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Operating Expenses data on file, last reported at $14.9 million in Q1 2026.

• Quarterly Operating Expenses rose 88.73% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.6 million (up 125.6% YoY) and the FY2025 annual result came in at $38.6 million, up 173.87% from the prior year.
• Operating Expenses advanced to $14.9 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $31.3 million in Q3 2023 and bottomed at -$54.9 million in Q4 2023.
• The 5-year median for Operating Expenses is $10.7 million (2025), against an average of $8.2 million.
• The widest annual swing landed in 2024, when Operating Expenses sank 89.92%; it then soared 347.47% in 2025.
• Tracing PVLA's Operating Expenses over 5 years: stood at $17.5 million in 2022, then plunged by 413.02% to -$54.9 million in 2023, then jumped by 107.95% to $4.4 million in 2024, then jumped by 158.91% to $11.3 million in 2025, then soared by 31.41% to $14.9 million in 2026.
• Per Business Quant, the three latest PVLA Operating Expenses figures stand at $14.9 million (Q1 2026), $11.3 million (Q4 2025), and $10.2 million (Q3 2025).

Peer Comparison